© Getty Images

Q&A: The potential of immuno-oncology - a view from the R&D department

By Isabel Cameron

Cancer immunotherapy, more commonly known as immuno-oncology, continues to gather momentum. As a rapidly evolving field, ongoing research and advancements are coming together to expand the number of available treatments, many of which are showing incredible...


Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda

By Rachel Arthur

An mRNA cancer vaccine, in combination with Keytruda, reduced the risk of recurrence or death in melanoma patients by 44% compared to Keytruda alone, according to Phase 2b data. Merck and Moderna plan to initiate a Phase 3 study in the coming months.

© GettyImages/koto_feja

Dispatches from Bio Digital 2021

Mogrify looks to transform cell therapy development

By Jane Byrne

Biotech, Mogrify, recently closed a Series A financing of US$17m, bringing the total raised to US$33m in the round, with the investment set to support the advancement of the company’s immuno-oncology and ophthalmology programs.